These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 20371479)

  • 1. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.
    Saito Y; Kitamura H; Hijikata A; Tomizawa-Murasawa M; Tanaka S; Takagi S; Uchida N; Suzuki N; Sone A; Najima Y; Ozawa H; Wake A; Taniguchi S; Shultz LD; Ohara O; Ishikawa F
    Sci Transl Med; 2010 Feb; 2(17):17ra9. PubMed ID: 20371479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.
    Sadovnik I; Hoelbl-Kovacic A; Herrmann H; Eisenwort G; Cerny-Reiterer S; Warsch W; Hoermann G; Greiner G; Blatt K; Peter B; Stefanzl G; Berger D; Bilban M; Herndlhofer S; Sill H; Sperr WR; Streubel B; Mannhalter C; Holyoake TL; Sexl V; Valent P
    Clin Cancer Res; 2016 Apr; 22(8):2051-61. PubMed ID: 26607600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
    Pelosi E; Castelli G; Testa U
    Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
    Saito Y; Yuki H; Kuratani M; Hashizume Y; Takagi S; Honma T; Tanaka A; Shirouzu M; Mikuni J; Handa N; Ogahara I; Sone A; Najima Y; Tomabechi Y; Wakiyama M; Uchida N; Tomizawa-Murasawa M; Kaneko A; Tanaka S; Suzuki N; Kajita H; Aoki Y; Ohara O; Shultz LD; Fukami T; Goto T; Taniguchi S; Yokoyama S; Ishikawa F
    Sci Transl Med; 2013 Apr; 5(181):181ra52. PubMed ID: 23596204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
    Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
    Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD25 targeted therapy of chemotherapy resistant leukemic stem cells using DR5 specific TRAIL peptide.
    Madhumathi J; Sridevi S; Verma RS
    Stem Cell Res; 2017 Mar; 19():65-75. PubMed ID: 28076753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
    Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
    Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
    Kikushige Y; Miyamoto T
    Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
    Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
    J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotyping and Target Expression Profiling of CD34
    Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
    Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y; Miyamoto T
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.